Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 58

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Colorectal cancer metastatic

Not recruiting

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Crohn's disease

Not recruiting

A study of the effects of AGMB-129 and midazolam in healthy participants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Midazolam
  • Sponsor:Agomab Spain S.L.U.

Eosinophilic oesophagitis+3

Not recruiting

Pharmacokinetics and Safety of Single Oral Etrasimod Arginine in Healthy Adults for Ulcerative Colitis Using At-Home Tasso Sampling and Wearable Monitoring

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Short-bowel syndrome

Not recruiting

Relative Bioavailability of Apraglutide in Prefilled Syringe versus Vial after Subcutaneous Injection in Healthy Subjects

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

Colitis ulcerative+4

Not recruiting

Pharmacokinetic Study of Ritlecitinib Tosilate in Healthy Adults: Oral Solution, Short‑and Long‑Duration Capsules Fed vs Fasted – for ulcerative colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Pfizer Inc.

Cystic fibrosis

Not recruiting

Bioequivalence Study of Ivacaftor 150 mg Film‑Coated Tablets in Healthy Adults for Cystic Fibrosis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · Healthy volunteers
  • Substances:Ivacaftor
  • Sponsor:Sun Pharmaceutical Industries Limited

Gastrointestinal carcinoma

Not recruiting

A Study of Raludotatug Deruxtecan for People with Gastrointestinal Cancers to Evaluate Safety and Effectiveness

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Raludotatug Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+6

Not recruiting

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cldn6 Car-T
  • Sponsor:BioNTech Cell & Gene Therapies GmbH

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+4

Not recruiting

A study comparing how ritlecitinib capsules work when sprinkled on food versus swallowed whole and with or without food in healthy adults

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Pfizer Inc.

Crohn's disease

Not recruiting

A study using the radiotracer vercirnon to examine its distribution in the body of healthy participants for research on Crohn's disease

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:VERCIRNON
  • Sponsor:AstraZeneca AB

Systemic scleroderma+3

Not recruiting

A Study of Cizutamig for Patients with Severe Autoimmune Inflammatory Diseases That Did Not Respond to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.